Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 82

1.

Acceptability of short term neo-adjuvant androgen deprivation in patients with locally advanced prostate cancer.

Lamb DS, Denham JW, Mameghan H, Joseph D, Turner S, Matthews J, Franklin I, Atkinson C, North J, Poulsen M, Kovacev O, Robertson R, Francis L, Christie D, Spry NA, Tai KH, Wynne C, Duchesne G.

Radiother Oncol. 2003 Sep;68(3):255-67.

PMID:
13129633
3.

Endocrine treatment of prostate cancer.

Tammela T.

J Steroid Biochem Mol Biol. 2004 Nov;92(4):287-95. Epub 2004 Dec 31. Review.

PMID:
15663992
4.

Locally advanced prostate cancer: effective treatments, but many adverse effects.

[No authors listed]

Prescrire Int. 2013 Jan;22(134):18-20, 22-3. Review.

PMID:
23367679
5.

What is the role of androgen deprivation therapy in the treatment of locally advanced prostate cancer?

Kollmeier MA, Zelefsky MJ.

Nat Clin Pract Urol. 2008 Nov;5(11):584-5. doi: 10.1038/ncpuro1217. Epub 2008 Sep 23. Review.

PMID:
18813218
6.

Radiation and hormonal therapy for locally advanced and clinically localized prostate cancer.

D'Amico AV.

Urology. 2002 Sep;60(3 Suppl 1):32-7; discussion 37-8. Review.

PMID:
12231043
7.

Adjuvant androgen deprivation therapy augments cure and long-term cancer control in men with poor prognosis, nonmetastatic prostate cancer.

Fleshner N, Keane TE, Lawton CA, Mulders PF, Payne H, Taneja SS, Morris T.

Prostate Cancer Prostatic Dis. 2008;11(1):46-52. Epub 2007 Jul 3. Review.

PMID:
17607304
8.

A systematic overview of radiation therapy effects in prostate cancer.

Nilsson S, Norlén BJ, Widmark A.

Acta Oncol. 2004;43(4):316-81. Review.

PMID:
15303499
9.

Luteinising hormone releasing hormone analogues in the treatment of prostate cancer.

Gommersall LM, Hayne D, Shergill IS, Arya M, Wallace DM.

Expert Opin Pharmacother. 2002 Dec;3(12):1685-92. Review.

PMID:
12472366
11.

Neoadjuvant total androgen suppression and radiotherapy in the management of locally advanced prostate cancer.

Roach M 3rd.

Semin Urol Oncol. 1996 May;14(2 Suppl 2):32-7; discussion 38. Review.

PMID:
8725889
12.

First-line treatment of metastatic prostate cancer. Androgen suppression for symptomatic disease.

[No authors listed]

Prescrire Int. 2013 Feb;22(135):48-51. Review.

PMID:
23444510
13.

Endocrine treatment in prostate cancer.

Denis LJ, Griffiths K.

Semin Surg Oncol. 2000 Jan-Feb;18(1):52-74. Review.

PMID:
10617897
16.

Risks and benefits of hormonal manipulation as monotherapy or adjuvant treatment in localised prostate cancer.

Abrahamsson PA, Anderson J, Boccon-Gibod L, Schulman C, Studer UE, Wirth M.

Eur Urol. 2005 Dec;48(6):900-5. Epub 2005 Oct 11. Review.

PMID:
16257109
17.
18.

[First line therapy in the treatment of metastatic prostate cancer].

Sakai H, Kanetake H.

Gan To Kagaku Ryoho. 2003 Jan;30(1):43-9. Review. Japanese.

PMID:
12557704
19.

Side effects of androgen deprivation therapy: monitoring and minimizing toxicity.

Higano CS.

Urology. 2003 Feb;61(2 Suppl 1):32-8. Review.

PMID:
12667885
20.

[Anti-androgen withdrawal syndrome].

Breul J, Paul R.

Urologe A. 1998 Mar;37(2):156-8. Review. German.

PMID:
9563126

Supplemental Content

Support Center